<DOC>
	<DOCNO>NCT01487044</DOCNO>
	<brief_summary>Establish efficacy initial high frequency load intravitreal pegaptanib bi-weekly initial treatment period VEGF level great gradually extend administration frequency monthly homeostasis ensues treatment DME , measure best-corrected visual acuity .</brief_summary>
	<brief_title>A Single-Center Trial High Frequency Pegaptanib Rapid Restoration VEGF Levels Diabetic Retinal Edema</brief_title>
	<detailed_description>Determine high frequency load intravitreal pegaptanib reduce area and/or volume DME , assess Spectral Domain optical coherence tomography ( SD-OCT ) determine load gradual taper schedule intravitreal pegaptanib reduce need macular laser treatment .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Papilledema</mesh_term>
	<criteria>Type I Type II diabetic , age 18 year old Vision 20/4020/400 Study Eye Diabetic Macular Edema document SDOCT Fluorescein Angiogram . Can attened trail require visit Eyes retinal surgery need likely need within 6 month , surgeon believe respond nonsurgical intervention . Presence abnormality likely confound assessment visual acuity improvement eye macular edema resolve , improves , nonperfusion great 1 disc area involve foveal avascular zone , epiretinal membrane associate sign contraction and/or significant opacification , presence chorioretinal atrophy involve center macula . Vitreomacular traction determine clinically and/or OCT , , investigator 's opinion , contribute macular edema , cause associated foveal detachment , would preclude improvement pegaptanib sodium . Previous treatment intravitreal corticosteroid study eye within 3 month Day 0 visit . Previous treatment intravitreal antiangiogenic drug study eye within 2 month Day 0 visit . Previous intraocular surgery within 30 day Day 0 visit . Any ocular periocular infection within 30 day Day 0 visit . Any following underlying disease include : History evidence severe cardiac disease ( e.g. , NYHA Functional Class III IV see Appendix 16.6 ) , clinical medical history unstable angina , acute coronary syndrome , myocardial infarction revascularization within 6 month , ventricular tachyarrythmias require ongoing treatment . History evidence clinically significant peripheral vascular disease , intermittent claudication prior amputation . History evidence clinically significant impaired renal hepatic function Stroke ( within 12 month trial entry ) . Any major surgical procedure within one month trial entry . Any treatment investigational agent past 30 day condition . Known serious allergy fluorescein dye use angiography component pegaptanib sodium formulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>DME</keyword>
</DOC>